Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PH-10 is a topical hydrogel formulation developed by Provectus Pharmaceuticals, containing rose bengal disodium, a small molecule belonging to the class of halogenated xanthenes. It is designed for the treatment of inflammatory dermatoses such as atopic dermatitis and psoriasis. The drug functions by undergoing photochemical reactions when activated by ambient light, leading to the down-regulation and normalization of various disease-related genes, including IL-17A, IL-22, IL-26, IL-36, keratin 16, IL-23, S100A7, IL-19, and CXCL1, and modulating pathways involving IL-17, IL-22, and interferons, thereby ameliorating skin inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PH-10.